Palvella Therapeutics (PVLA) Receivables (2013 - 2024)
Palvella Therapeutics (PVLA) reported Receivables of $358000.0 for Q4 2024, down 84.61% year-over-year from $2.3 million in Q1 2024, and down 4.02% on a QoQ basis from $373000.0 in Q3 2024.
Palvella Therapeutics (PVLA) has 11 years of Receivables data on file, last reported at $358000.0 in Q4 2024.
- Quarterly Receivables fell 84.61% year-over-year to $358000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $358000.0 (down 84.61% YoY) and the FY2024 annual result came in at $358000.0, down 84.61% from the prior year.
- Receivables eased to $358000.0 in Q4 2024 per PVLA's latest filing, from $373000.0 in the prior quarter.
- Across five years, Receivables topped out at $17.0 million in Q2 2021 and bottomed at $358000.0 in Q4 2024.
- The 5-year median for Receivables is $2.6 million (2020), against an average of $5.3 million.
- The widest annual swing landed in 2021, when Receivables surged 477.45%; it then slumped 95.12% in 2022.
- Tracing PVLA's Receivables over 5 years: stood at $1.7 million in 2020, then jumped by 94.2% to $3.3 million in 2021, then surged by 219.38% to $10.6 million in 2022, then tumbled by 78.02% to $2.3 million in 2023, then tumbled by 84.61% to $358000.0 in 2024.
- Per Business Quant, the three latest PVLA Receivables figures stand at $358000.0 (Q4 2024), $373000.0 (Q3 2024), and $4.5 million (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 358,000.00 |
| Sep 30, 2024 | 373,000.00 |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 952,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 10.58 Mn |
| Sep 30, 2022 | 829,000.00 |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 3.31 Mn |
| Sep 30, 2021 | 17.00 Mn |
| Jun 30, 2021 | 17.00 Mn |
| Mar 31, 2021 | 15.81 Mn |
| Dec 31, 2020 | 1.71 Mn |
| Sep 30, 2020 | 2.94 Mn |
| Jun 30, 2020 | 10.71 Mn |
| Mar 31, 2020 | 7.27 Mn |
| Dec 31, 2019 | 7.09 Mn |
| Sep 30, 2019 | 6.95 Mn |
| Jun 30, 2019 | 7.17 Mn |
| Mar 31, 2019 | 7.13 Mn |
| Dec 31, 2018 | 2.70 Mn |
| Sep 30, 2018 | 5.34 Mn |
| Jun 30, 2018 | 2.56 Mn |
| Mar 31, 2018 | 3.31 Mn |
| Dec 31, 2017 | 15.55 Mn |
| Sep 30, 2017 | 2.54 Mn |
| Jun 30, 2017 | 48.47 Mn |
| Mar 31, 2017 | 39,013.00 |
| Dec 31, 2016 | 57,000.00 |
| Mar 31, 2016 | 70,259.00 |
| Sep 30, 2015 | 17,358.00 |
| Dec 31, 2013 | 481,810.00 |